

Sanofi  
Form 6-K  
July 29, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July 2016**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

**(Address of principal executive offices)**

Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

In July 2016, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1 to 99.5 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated July 29, 2016: 2 <sup>nd</sup> quarter and half year Results for 2016
Exhibit 99.2	Press release dated July 27, 2016: Sanofi Receives FDA Approval of Adlyxin <sup>TM</sup> for Treatment of Adults with Type 2 Diabetes
Exhibit 99.3	Press release dated July 6, 2016: Sanofi Pasteur Signs Research Agreement for Zika Vaccine
Exhibit 99.4	Press release dated July 5, 2016: Sanofi and Regeneron Announce Approval of Praluent <sup>®</sup> (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period Ended June 30, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 29, 2016

SANOFI

By /S/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Securities Law and Capital Markets

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated July 29, 2016: 2 <sup>nd</sup> quarter and half year Results for 2016
Exhibit 99.2	Press release dated July 27, 2016: Sanofi Receives FDA Approval of Adlyxin <sup>TM</sup> for Treatment of Adults with Type 2 Diabetes
Exhibit 99.3	Press release dated July 6, 2016: Sanofi Pasteur Signs Research Agreement for Zika Vaccine
Exhibit 99.4	Press release dated July 5, 2016: Sanofi and Regeneron Announce Approval of Praluent <sup>®</sup> (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period Ended June 30, 2016